Key result
Oral conjugated equine estrogens cut odds of epicardial adipose tissue accumulation by ~38% vs placebo.
Why the study?
Heart fats are greater after menopause and may be regulated by endogenous estrogen, but the differential effects of hormone therapy formulations on heart fat accumulation and CAC progression were unknown.
Does hormone therapy (oral conjugated equine estrogens or transdermal 17β-estradiol) affect heart fat accumulation and CAC progression in early menopausal women?
RCT (n=474)
Double-blind
Randomized
Yes
Does hormone therapy (oral conjugated equine estrogens or transdermal 17β-estradiol) affect heart fat accumulation and CAC progression in early menopausal women?
In early menopausal women, oral conjugated equine estrogens may slow epicardial adipose tissue accumulation, whereas transdermal 17β-estradiol may increase CAC progression associated with paracardial fat accumulation.
Answers are grounded in this paper and cite their sources.
May slow epicardial fat accumulation with oral estrogens in early menopause; extends RCT evidence on hormone therapy and cardiac adiposity.
Background Heart fats (epicardial and paracardial adipose tissue [PAT]) are greater after menopause. Endogenous estrogen may regulate these fat depots. We evaluated the differential effects of hormone therapy formulations on heart fat accumulations and their associations with coronary artery calcification ( CAC ) progression in recently menopausal women from KEEPS (Kronos Early Estrogen Prevention Study). Methods and Results KEEPS was a multicenter, randomized, placebo‐controlled trial of the effects of 0.45 mg/d oral conjugated equine estrogens and 50 µg/d transdermal 17β‐estradiol, compared with placebo, on 48‐month progression of subclinical atherosclerosis among 727 early menopausal women. CAC progression was defined if baseline CAC score was 0 and 48‐month CAC score was >0 or if baseline CAC score was >0 and <100 and annualized change in CAC score was ≥10. Of 727 KEEPS participants, 474 (mean age: 52.7 [SD: 2.6]; 78.1% white) had computed tomography–based heart fat and CAC measures at both baseline and 48 months. Compared with women on placebo, women on oral conjugated equine estrogens were less likely to have any increase in epicardial adipose tissue (odds ratio for oral conjugated equine estrogens versus placebo: 0.62 [95% CI, 0.40–0.97]; P =0.03). PAT did not change in any group. Changes in epicardial adipose tissue and PAT did not differ by treatment group. CAC increased in 14% of participants. The assigned treatment modified the association between PAT changes and CAC progression ( P =0.02) such that PAT increases were associated with CAC increases only in the transdermal 17β‐estradiol group. Conclusions In recently menopausal women, oral conjugated equine estrogens may slow epicardial adipose tissue accumulation, whereas transdermal 17β‐estradiol may increase progression of CAC associated with PAT accumulation. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00154180.
No takes yet. Share an insight, caveat, or question.
Khoudary et al. (2019) conducted an RCT in Subclinical atherosclerosis and heart fat accumulation in recently menopausal women (n=474). Oral conjugated equine estrogens (o-CEE) or transdermal 17β-estradiol (t-E2) vs. Placebo (inactive pill and patch) was evaluated on Any increase in epicardial adipose tissue (EAT) volume over 48 months (o-CEE vs placebo) (OR 0.62, 95% CI 0.40-0.97, p=0.03). Oral conjugated equine estrogens reduced the odds of epicardial adipose tissue accumulation over 48 months compared with placebo in recently menopausal women.
Synapse has enriched 10 related papers. Consider them for comparative context: